Injection-free exenatide improves diabetes markers

10/3/2012 | Healio

Type 2 diabetes patients who received the injection-free exenatide ITCA 650 attained significant improvements in body weight, HbA1C, fasting plasma glucose and postprandial glucose levels, with greater effects seen in those who received higher doses than those who took a lower dose. However, researchers said 40 mcg and 60 mcg doses of ITCA 650 were better tolerated compared with the 80 mcg dose. The findings were presented at the European Association for the Study of Diabetes meeting.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ